Hartman Institute for Therapeutic Organ Regeneration

Angiomodulin is a specific marker of vasculature and regulates vascular endothelial growth factor-A-dependent neoangiogenesis.

TitleAngiomodulin is a specific marker of vasculature and regulates vascular endothelial growth factor-A-dependent neoangiogenesis.
Publication TypeJournal Article
Year of Publication2009
AuthorsHooper AT, Shmelkov SV, Gupta S, Milde T, Bambino K, Gillen K, Goetz M, Chavala S, Baljevic M, Murphy AJ, Valenzuela DM, Gale NW, Thurston G, Yancopoulos GD, Vahdat L, Evans T, Rafii S
JournalCirc Res
Volume105
Issue2
Pagination201-8
Date Published2009 Jul 17
ISSN1524-4571
KeywordsAnimals, Cell Line, Tumor, Disease Models, Animal, Female, Gene Expression Regulation, Developmental, Gene Knockdown Techniques, Genotype, Humans, Male, Mice, Mice, Inbred C57BL, Mice, Transgenic, Morpholines, Neoplasm Proteins, Neoplasms, Neovascularization, Pathologic, Neovascularization, Physiologic, Oligonucleotides, Antisense, Phenotype, Promoter Regions, Genetic, Retinal Neovascularization, Signal Transduction, Skin, Vascular Endothelial Growth Factor A, Vascular Endothelial Growth Factor Receptor-2, Wound Healing, Zebrafish, Zebrafish Proteins
Abstract

<p>Blood vessel formation is controlled by the balance between pro- and antiangiogenic pathways. Although much is known about the factors that drive sprouting of neovessels, the factors that stabilize and pattern neovessels are undefined. The expression of angiomodulin (AGM), a vascular endothelial growth factor (VEGF)-A binding protein, was increased in the vasculature of several human tumors as compared to normal tissue, raising the hypothesis that AGM may modulate VEGF-A-dependent vascular patterning. To elucidate the expression pattern of AGM, we developed an AGM knockin reporter mouse (AGM(lacZ/+)), with which we demonstrate that AGM is predominantly expressed in the vasculature of developing embryos and adult organs. During physiological and pathological angiogenesis, AGM is upregulated in the angiogenic vasculature. Using the zebrafish model, we found that AGM is restricted to developing vasculature by 17 to 22 hours postfertilization. Blockade of AGM activity with morpholino oligomers results in prominent angiogenesis defects in vascular sprouting and remodeling. Concurrent knockdown of both AGM and VEGF-A results in synergistic angiogenesis defects. When VEGF-A is overexpressed, the compensatory induction of the VEGF-A receptor, VEGFR2/flk-1, is blocked by the simultaneous injection of AGM morpholino oligomers. These results demonstrate that the vascular-specific marker AGM modulates vascular remodeling in part by temporizing the proangiogenic effects of VEGF-A.</p>

DOI10.1161/CIRCRESAHA.109.196790
Alternate JournalCirc Res
PubMed ID19542015
PubMed Central IDPMC2936249
Grant ListR01HL075234 / HL / NHLBI NIH HHS / United States
P01 HL059312-090006 / HL / NHLBI NIH HHS / United States
R01 HL061849-04 / HL / NHLBI NIH HHS / United States
R01 HL056182 / HL / NHLBI NIH HHS / United States
R01 HL061849-03S1 / HL / NHLBI NIH HHS / United States
U01 HL066952-040002 / HL / NHLBI NIH HHS / United States
P01 HL059312-080006 / HL / NHLBI NIH HHS / United States
R01 HL075234 / HL / NHLBI NIH HHS / United States
R21 HL083222-01 / HL / NHLBI NIH HHS / United States
R01 HL075234-04 / HL / NHLBI NIH HHS / United States
U01 HL066952 / HL / NHLBI NIH HHS / United States
P01 HL067839-020004 / HL / NHLBI NIH HHS / United States
P01 HL072942-010004 / HL / NHLBI NIH HHS / United States
R21HL083222-02 / HL / NHLBI NIH HHS / United States
P50 HL084936 / HL / NHLBI NIH HHS / United States
R01 HL058707-04 / HL / NHLBI NIH HHS / United States
P01 HL059312-100006 / HL / NHLBI NIH HHS / United States
P01 HL072942 / HL / NHLBI NIH HHS / United States
R01 HL064282 / HL / NHLBI NIH HHS / United States
U01 HL066952-030002 / HL / NHLBI NIH HHS / United States
P50 HL084936-010003 / HL / NHLBI NIH HHS / United States
R21 HL083222-02 / HL / NHLBI NIH HHS / United States
P50 HL084936-030003 / HL / NHLBI NIH HHS / United States
P01 HL067839 / HL / NHLBI NIH HHS / United States
R01 HL075234-03 / HL / NHLBI NIH HHS / United States
U01 HL066952-020002 / HL / NHLBI NIH HHS / United States
R01 HL058707-03 / HL / NHLBI NIH HHS / United States
P01 HL059312-060006 / HL / NHLBI NIH HHS / United States
K08 EY021171 / EY / NEI NIH HHS / United States
P50 HL084936-020003 / HL / NHLBI NIH HHS / United States
P01 HL059312 / HL / NHLBI NIH HHS / United States
R01 HL061849-03 / HL / NHLBI NIH HHS / United States
R01HL059312 / HL / NHLBI NIH HHS / United States
R01 HL061849 / HL / NHLBI NIH HHS / United States
R01 HL075234-02 / HL / NHLBI NIH HHS / United States
R01 HL061849-05 / HL / NHLBI NIH HHS / United States
P01 HL067839-050004 / HL / NHLBI NIH HHS / United States
P01 HL067839-030004 / HL / NHLBI NIH HHS / United States
P01 HL059312-070006 / HL / NHLBI NIH HHS / United States
P50 HL084936-040003 / HL / NHLBI NIH HHS / United States
R37 HL056182 / HL / NHLBI NIH HHS / United States
P01 HL067839-010004 / HL / NHLBI NIH HHS / United States
R01HL056182 / HL / NHLBI NIH HHS / United States
R01 HL075234-01 / HL / NHLBI NIH HHS / United States
R01 HL061849-02 / HL / NHLBI NIH HHS / United States
U01 HL066952-050002 / HL / NHLBI NIH HHS / United States
U01 HL066952-010002 / HL / NHLBI NIH HHS / United States
/ HHMI / Howard Hughes Medical Institute / United States
P01 HL067839-040004 / HL / NHLBI NIH HHS / United States
R21 HL083222 / HL / NHLBI NIH HHS / United States
R01HL064282 / HL / NHLBI NIH HHS / United States

Weill Cornell Medicine
Hartman Institute for Therapeutic Organ Regeneration
1300 York Ave, Box 136 New York, NY 10065